"Yes" and "no" are rather broad brush answers. Progress occurs in increments in these areas.
If you can model a patient, you can automate the analysis. It is forseeable that basic types of genetic makeup of various patients could be modeled. This could come out of the work in "personal medicine" to see which sorts of patients may be cured by a molecule and which sorts of patients may be killed by it.
As further validity of new forms of modeling is established, automation can be tested. The automated testing could be used side by side in a Phase 1 clinical trial. This would be a first step.
Yes, everything is going to automate and using AI it will happen soon.
The FDA will never go for it.
Not gonna happen.
"Yes" and "no" are rather broad brush answers. Progress occurs in increments in these areas.
If you can model a patient, you can automate the analysis. It is forseeable that basic types of genetic makeup of various patients could be modeled. This could come out of the work in "personal medicine" to see which sorts of patients may be cured by a molecule and which sorts of patients may be killed by it.
As further validity of new forms of modeling is established, automation can be tested. The automated testing could be used side by side in a Phase 1 clinical trial. This would be a first step.